Identifying and targeting escape mechanisms in AML using multispecific antibody derivatives (A10)

• Subject Area: Hematology, Oncology ; Biochemistry ; Immunology
• Term: from 2016 to 2020
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 278529602

Treatment of AML by allogeneic stem cell transplantation is mediated by T cells but is hampered by a high mortality rate. We find that T-cell function is modulated through progressively evolving changes in phenotype and function of AML and its tumor microen¬vironment (TME). Our goal is to unravel changes in T-cell responses and develop multi-specific antibody derivatives (msADs), tailored to interfere with immune checkpoint molecules in specific geno- and phenotype of AML subtypes.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 1243: Genetic and Epigenetic Evolution of Hematopoietic Neoplasms
• Applicant Institution: Ludwig-Maximilians-Universität München
• Project Heads: Professor Dr. Karl-Peter Hopfner; Professorin Dr. Marion Subklewe